Insulet Co. (NASDAQ:PODD - Get Free Report) Director Wayne A.I. Frederick sold 1,825 shares of the company's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the transaction, the director now owns 3,231 shares of the company's stock, valued at approximately $888,525. The trade was a 36.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Insulet Stock Down 2.9 %
Shares of NASDAQ:PODD opened at $264.88 on Thursday. The business's 50 day moving average is $272.28 and its 200 day moving average is $258.24. The stock has a market cap of $18.60 billion, a P/E ratio of 45.75, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $289.46. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.
Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.00 by $0.15. The business had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. Sell-side analysts predict that Insulet Co. will post 3.92 EPS for the current year.
Institutional Investors Weigh In On Insulet
Several large investors have recently modified their holdings of PODD. Integrated Wealth Concepts LLC increased its holdings in Insulet by 1.7% during the third quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier's stock valued at $596,000 after buying an additional 42 shares during the period. Horizon Investments LLC increased its holdings in shares of Insulet by 3.1% in the 4th quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier's stock valued at $362,000 after acquiring an additional 42 shares during the period. Nisa Investment Advisors LLC raised its position in shares of Insulet by 1.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier's stock worth $1,146,000 after acquiring an additional 43 shares in the last quarter. Glenmede Trust Co. NA lifted its stake in shares of Insulet by 2.3% during the 3rd quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier's stock worth $484,000 after purchasing an additional 47 shares during the last quarter. Finally, Graypoint LLC boosted its position in Insulet by 5.3% during the fourth quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier's stock valued at $243,000 after purchasing an additional 47 shares in the last quarter.
Analyst Ratings Changes
Several brokerages have recently commented on PODD. Piper Sandler boosted their price objective on Insulet from $285.00 to $310.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. Raymond James reiterated an "outperform" rating and set a $328.00 price objective (up previously from $294.00) on shares of Insulet in a research report on Friday, February 21st. StockNews.com cut Insulet from a "buy" rating to a "hold" rating in a report on Tuesday, March 4th. Citigroup increased their price target on Insulet from $310.00 to $355.00 and gave the company a "buy" rating in a report on Friday, February 21st. Finally, TD Cowen lifted their price objective on shares of Insulet from $264.00 to $324.00 and gave the stock a "buy" rating in a research note on Friday, January 3rd. Four investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, Insulet presently has an average rating of "Moderate Buy" and an average target price of $292.06.
Get Our Latest Research Report on Insulet
Insulet Company Profile
(
Get Free Report)
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
